Localized Prostate Carcinoma, Locally Advanced Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Conditions
Brief summary
This clinical trial evaluates a golf recreational exercise program for enhancing survivorship in underrepresented prostate cancer survivors. Golf is a multimodal recreational activity that requires participants to utilize all muscle groups to perform the golf swing, walk over hilly and uneven terrain, maintain balance during putting and squat-like tasks. Physical activity and exercise are beneficial to physical function, cognitive function, psychosocial health, and overall quality of life during prostate cancer survivorship. These aspects of health are impacted by prostate cancer treatment, especially androgen deprivation therapy. Additionally, supervised, group-based activity programs facilitate participation in physical activity. Researchers want to examine the changes in functional abilities, psychosocial health, and quality of life following participation in in a golf program designed for prostate cancer survivors.
Detailed description
PRIMARY OBJECTIVES: I. To recruit, screen, and enroll prostate cancer survivors. II. To examine the safety, feasibility, and adherence, of the 10-week (wk) GREENS program. III. To analyze the pre-post intervention data and examine the effects (assessed by Hedges g) of the program on: IIIa. Physical capacity; IIIb. Psychosocial wellness; IIIc. Health, and; IIId. Cognition. OUTLINE: Patients participate in the golf training program composed of group sessions over 1-2 hours with a Professional Golfers' Association of America (PGA) professional two times per week for ten weeks. Training consists of complimentary/warm up exercises integrated with pelvic floor muscle training, golf instruction, golf practice, and golf play on a Par 3 public golf course. Patients also wear an activity tracker and undergo blood sample collection on the study. After completion of study intervention, patients are followed up at 6 months.
Interventions
PROCEDUREBiospecimen Collection
Undergo blood sample collection
PROCEDUREDiscussion
Ancillary studies
OTHERExercise Intervention
Complete golf related exercises
OTHERInterview
Ancillary studies
OTHERMedical Device Usage and Evaluation
Wear activity tracker
PROCEDUREPhysical Examination
Ancillary studies
OTHERPhysical Performance Testing
Ancillary studies
OTHERQuestionnaire Administration
Ancillary studies
OTHERRecreational Therapy
Participate in golf program
Sponsors
University of Southern California
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
55 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* First time, primary diagnosis of prostate cancer (PCa) * Currently receiving androgen deprivation therapy (ADT) and/or androgen receptor blocker) for more than 6 months * Older adult male: 55-85 years old * The ability to stand independently without external support * No or minimal golf experience (played \< 5 times in the past 10 years) * English speaking
Exclusion criteria
* Second cancer diagnosis (excluding non-invasive skin cancers) or bone metastases * Prostatectomy less than 6 months prior to study enrollment (prostatectomy is not a requirement for study entry) * Symptomatic cardiovascular disease, active angina, uncontrolled hypertension (systolic blood pressure (SBP) \> 160 or diastolic blood pressure (DBP) \> 90, high resting pulse heart rate (HR) \> 90), symptomatic orthostatic hypotension * Unstable asthma, exacerbated chronic obstructive pulmonary disease (COPD\] * History of injury or orthopedic operation within the last 6 months * Movement disorders (e.g., Parkinson's disease (PD) or other neurological disorders), hemiparesis or paraparesis * Severe vision or hearing problems
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Enrollment rate | Up to 3 years | Will be defined as the final number of enrolled individuals / the number of qualified individuals screened. |
| Participant adherence to the program | Up to 3 years | Will be assessed by the number of participants who adhere to the study and attend \> 80% of supervised training sessions. |
| Cost of the program | Up to 3 years | Will be assessed by the cost that the program will be \< $1,000/participant. |
| Staff adherence | Up to 3 years | Will be assessed by trained staff who attend \> 90% of scheduled sessions. |
| Program accommodations | Up to 3 years | Will be defined as the program accommodating course scheduling for \> 95% of training sessions. |
| Incidence of adverse events | Up to 3 years | Will be assessed across all participants, and defined by less than 3 program-related adverse events (AEs) and any/all AEs will be mild (grade 3 or below according to Common Terminology Criteria for Adverse Events version 5). |
| Quality of life scores | Up to 3 years | Will be assessed by the Functional Assessment of Cancer Therapy - Prostate (FACT-P), a 39-item self-reported questionnaire. FACT-P scores range from 0 to 156, with higher scores indicating a better quality of life. It is expected that the scores will improve with medium to large effect sizes and exceed the established minimal clinically important difference (MCID). |
| Circulating inflammatory biomarker levels | Up to 3 years | Will be assessed by C-reactive protein and tumor necrosis factor alpha (TNFa) which are indicators of inflammation. Based on prior study, C-reactive protein and TNFa levels are expected to decrease with medium to large effect sizes and exceed the calculated MCID levels. |
| Senior fitness test scores | Up to 3 years | Will be assessed by Short physical performance battery (SPPB). The SPPB is scored out of 12 points and higher score indicates better performance. The SPPB is a reliable (intraclass correlation coefficient \[ICC\] was between 0.82-0.92) and validated (MDC=2; MCID=1-3) measure for physical capacity in community-dwelling and clinical older adults. |
| Gait speed | Up to 3 years | Will be assessed with self-selected gait and fast gait using a 10-feet designated walkway and timing device. Faster gait speeds in both condition indicate higher physical capacity. For reference, men in the 60-65 years age group, gait speeds over 1.53 m/s is considered above 80th percentile. |
| Balance Confidence | Up to 3 years | Will be assessed by Activities-specific Balance Confidence (ABC) scale, a 16-item self-reported questionnaire. The ABC is scored from 0% to 100%, where higher scores indicate greater confidence in maintaining balance during activities. |
| Cognitive function | Up to 3 years | Will be assessed by the Food and Drug Administration approved Sway Medical application (app) designed to assess cognition with a smart phone device and will be used to assess cognitive function. The app includes validated tests for processing speed, sensory processing, neuromotor response speed, inhibition, memory, and executive function, which are areas of cognitive function that are potentially influenced by prostate cancer treatments. The app has established normative values for different age group and will be used as reference. |
| Participant feedback of the program | Up to 3 years | Will be assessed by a semi-structured focus group that will be conducted post intervention where participants will be asked about positive affect and negative affect associated with the intervention, their perceived mastery of different components of golf (i.e. putting, chipping, golf swing, etiquette, rules, etc.), facilitators and barriers that pertained to their participation in the intervention. These assessments will provide information unique to prostate cancer survivors and be used directly to improve the protocol and intervention design for future studies in this population. The facilitators and barriers will also be compared to established ones reported by Sattar et al. to qualitatively assess whether they are similar with our diverse cohort of minority participants located in Los Angeles, California. |
Countries
United States
Contacts
CONTACTGarry Cai
PRINCIPAL_INVESTIGATORGeorge Salem, PhD
University of Southern California
Outcome results
None listed